Anti-SARS-CoV activity of nucleoside analogs having 6-chloropurine as a nucleobase

Masahiro Ikejiri; Masayuki Saijo; Shigeru Morikawa; Shuetsu Fukushi; Tetsuya Mizutani; Ichiro Kurane; Tokumi Maruyama

doi:10.1093/nass/nrl056

Anti-SARS-CoV activity of nucleoside analogs having 6-chloropurine as a nucleobase

Nucleic Acids Symp Ser (Oxf). 2006:(50):113-4. doi: 10.1093/nass/nrl056.

Authors

Masahiro Ikejiri¹, Masayuki Saijo, Shigeru Morikawa, Shuetsu Fukushi, Tetsuya Mizutani, Ichiro Kurane, Tokumi Maruyama

Affiliation

¹ Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki, Kagawa 769-2193, Japan.

PMID: 17150843
DOI: 10.1093/nass/nrl056

Abstract

Nucleoside analogs that have 6-chloropurine as a nucleobase were synthesized and evaluated to develop novel anti-SARS-CoV agents. Two compounds among them showed promising activity that was comparable to mizoribine and ribavirin. Moreover, one of the compounds showed a structurally unique property.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / chemical synthesis
Antiviral Agents / chemistry*
Antiviral Agents / pharmacology
Purine Nucleosides / chemical synthesis
Purine Nucleosides / chemistry*
Purine Nucleosides / pharmacology
Purines / chemistry*
Severe acute respiratory syndrome-related coronavirus / drug effects*
Severe acute respiratory syndrome-related coronavirus / growth & development
Viral Plaque Assay

Substances

Antiviral Agents
Purine Nucleosides
Purines
6-chloropurine